Search CommunityWalk:


Rafagen Inc

Maryland Technology Development Center, Suite 191
Rockville, MD, USA

Category: Bioinformatics/Genomics/Proteomics/Pharmacogenomics

Used in the following map:

Maryland Biotech Industry Map

Rafagen Inc is focused on the development and commercialization of next generation gene expression systems, with applications in molecular therapeutics. It was founded by Sung Ho Hahm, Ja Shin Koo and Oltac Unsal with a goal to become a leader of novel molecular therapeutics development.

Rafagen's technologies include: Synthetic Gene Promotor Technology, Gene Expression Vector Technologies, and Cell Line Selection Technologies. Its synthetic gene promotor technology enables high throughput production of synthetic gene promoters for patient treatment and for the use in maximizing protein/antibody drug production levels, respectively. The company is developing gene elements that can mimic the activities of chromosome insulators, a matrix attachment region, or other chromatin structure opening elements. These elements will be used in preventing positional effects and inactivation processes of the stably incorporated genes, resulting in a marked and sustained expression of the recombinant genes. It possesses proprietary FACS-aided and non-antibody-based technology for a rapid selection of highly expressing cell lines.

Rafagen's products include: Super Promoters, which are tailor made according to the need of a specific cell type or growth conditions; and Targeting Promoters (TPs) that allow cell type-specific gene expression at an unprecedented level of precision and efficiency. Its services include: cell line development for protein and monoclonal antibody drug production. The company also has expertise in the following areas: Gene Cloning, Codon Optimization, Library construction, Sequencing, DNA microarray, Gene Synthesis, Cell culture optimization, and Flow Cytometry.

Rafagen's partners include: Goodwin Biotechnology, Inc, UMBI - University of Maryland Biotechnology Institute, American Gene Technology International, Inc. (AGTII), Johns Hopkins University, National Institutes of Health, University of Maryland, Korea Research Institute of Bioscience and Biotechnology, and Korea Advanced Institute of Science and Technology (KAIST).